Compare Bristol-Myers Squibb Co (BMY) vs Enovix Corporation (ENVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Enovix Corporation — how do they compare? Bristol-Myers Squibb Co trades at $63.84 (market cap $129.94B), while Enovix Corporation trades at $4.81 (market cap $1.06B). The key difference: Bristol-Myers Squibb Co is far larger — about 122.6× Enovix Corporation's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Enovix Corporation pays none. Which is the better fit depends on your goals.
| BMY | ENVX | |
|---|---|---|
Market Cap | $129.94B | $1.06B |
Sector | Health | Technology |
52-Week High | $65.89 | $13.19 |
52-Week Low | $42.60 | $3.68 |
Enterprise Value | $163.92B | $1.07B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
ENVX trades at $4.92, up 6.03% in the last 24 hours, with a bullish technical signal despite negative profitability. Recent earnings beats and the appointment of a former Apple executive as COO highlight operational progress. The stock shows strong analyst support with a consensus price target of $12.38, though cash flow remains negative as the company scales production.
Outlook is cautiously optimistic given high growth potential in advanced battery technology, but significant execution risks and persistent losses require careful monitoring. The stock offers upside if production ramps successfully, but volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →
